1. EXECUTIVE SUMMARY

Oukang Vision Biomedical Co., Ltd. (known globally as Ocumension Therapeutics, and operating in domestic markets under the Chinese entity name 欧康维视生物 / Oukang Weishi Bio) is a leading China-based ophthalmic pharmaceutical platform company. Publicly listed on the Hong Kong Stock Exchange (HKEX: 01477), the company was established to address significant unmet medical needs in ophthalmic healthcare across China and Greater Asia.

Headquartered strategically in Suzhou and Shanghai, China, Oukang Vision operates an end-to-end pharmaceutical integration model. The company's platform spans initial drug discovery, target research and development (R&D), clinical trial management, high-standard regulatory compliance, state-of-the-art commercial manufacturing, and direct physician and hospital distribution networks.

1. CORE BUSINESS MODEL AND R&D ARCHITECTURE

Oukang Vision's core mission centers on delivering innovative treatments for front-of-the-eye and back-of-the-eye diseases. The organization employs a hybrid growth strategy combining internal target discovery with aggressive international licensing and asset acquisitions (in-licensing first-in-class and best-in-class therapies from global biopharmaceutical partners).

The company operates specialized operational pillars: * Integrated R&D Capabilities: In-house formulation optimization, non-clinical evaluation, and management of multi-center clinical trials for ophthalmic therapeutics. * Modern Manufacturing Infrastructure: Dedicated, commercial-scale production facilities located in Suzhou, engineered to comply with international GMP (Good Manufacturing Practice) standards set by the NMPA, US FDA, and European EMA. * Commercial Network: Direct commercial coverage of major ophthalmic centers, eye hospitals, and clinical departments across provinces in mainland China.

1. THERAPEUTIC FOCUS AND PRODUCT PORTFOLIO

Oukang Vision maintains a comprehensive pipeline consisting of commercialized drugs and late-stage clinical candidates targeting front- and back-of-the-eye conditions:

A. Front-of-the-Eye Pathologies * Dry Eye Disease (DED): Commercialized solutions including hyaluronic acid-based artificial tears (e.g., Ou Qin) alongside novel anti-inflammatory therapeutic pipelines targeting chronic ocular surface inflammation. * Ocular Allergy and Conjunctivitis: Formulations including OT-1001 (cetirizine/ZERVIATE) designed to provide rapid relief from allergic conjunctivitis symptoms. * Anti-Infective and Anti-Inflammatory Therapeutics: Ophthalmic solutions including 0.5% moxifloxacin eye drops, brimonidine tartrate drops, and post-operative anti-inflammatory agents such as OT-502 (DEXYCU).

B. Back-of-the-Eye (Retinal) Pathologies * Uveitis: Highlighted by OT-401 (fluocinolone acetonide intravitreal implant / YUTIQ), an innovative micro-insert engineered to provide continuous, low-dose corticosteroid release to control non-infectious uveitis affecting the posterior segment of the eye for extended periods. * Glaucoma and Ocular Hypertension: Advanced therapeutic pipeline candidates such as OT-301 (NCX 470), a novel nitric oxide-donating bimatoprost analog evaluated for intraocular pressure reduction. * Pediatric Myopia: Focus on slow-progression therapies, including low-concentration atropine formulations (such as OT-101) undergoing extensive clinical trials.

1. COMMERCIAL SERVICES AND INDUSTRY OPERATIONS

Beyond therapeutic manufacturing, Oukang Vision functions as an operational bridge between Western biopharmaceutical innovators and the Asian healthcare market:

• In-Licensing and Regional Commercialization: Partnering with global pharmaceutical firms to secure exclusive rights for development and sales in Greater China and neighboring territories.
• Contract Manufacturing & Supply Chain Solutions: Providing sterile liquid, suspension, and implant manufacturing services for ophthalmic formulations.

• Regulatory and Market Access Services: Managing complex national regulatory filings with China's National Medical Products Administration (NMPA), securing National Health Insurance (NRDL) inclusions, and facilitating distribution to thousands of top-tier hospitals.

  1. CORPORATE STRUCTURE AND OUTLOOK

Oukang Vision Biomedical has established itself as one of the premier dedicated ophthalmic platforms in China. By combining a broad therapeutic portfolio across dry eye, myopia, glaucoma, uveitis, and retinal diseases with scalable domestic manufacturing and localized clinical development, the company continues to advance the standard of care for millions of patients throughout China.